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An 11 % decrease in clearance is unlikely as sole explanation for the 
observed inter-individual variability in toxicity and therapeutic effects. The 
results are nevertheless important because:
1)  an impact of CYP2C8*3 has not been demonstrated before in similar 
studies 
2)  it fi ts well with the understanding of how a genotype can impact on a 
phenotype 
3)  it adds to the knowledge of factors that contribute to the variability of 
paclitaxel pharmakokinetics.
Discussion
Taxane pathway. Copyright 2009 PharmGKB reproduced with permission(2).
CYP3A4
CYP2C8
TUBA2
MAP4
MAPT
CSAG2
Cell Death
TUBB
ABCB1
NR1I2
CYP1B1
metabolite
metabolite
ABCC1ABCG2ABCC2
docetaxel/paclitaxel
CYP3A4
CYP2C8
CYP3A5
metabolite
metabolite
docetaxel/paclitaxel
Microtubule  
stabilization 
References
(1)  Henningsson et al. Association of CYP2C8, CYP3A5, and ABCB1 polymorphisms with 
the Pharmacokinetics of Paclitaxel. Clin Cancer Res 2005,15(22):8097-104
(2)  Klein et al. Integrating genotype and phenotype information: an overview of the 
PharmGKB project. Pharmacogenetics J 2001,1(3):167-70
Methods
Patients: Eligibility criteria included patients with primary ovarian 
cancer scheduled for therapy with paclitaxel (175mg/m2)+carboplatin 
(AUC5-6) every third week. Patients were recruited from four oncology 
departments in Denmark and one in Sweden from 2007 to 2009.
Blood sampling and paclitaxel and Cremophor EL analyses
Three consecutive samples were collected from one cycle from each patient. 
Sampling times were approximately 3 hours, 5-8 hours and 18-24 hours 
after start of paclitaxel infusion. The total paclitaxel concentration was 
determined by HPLC. Cremophor EL was determined using a Coomasie 
blue assay.
Pharmakokinetic analysis
Empirical Bayes´ estimates of clearance of unbound paclitaxel were achieved 
from total paclitaxel and cremophor EL concentrations in a non-linear 
mixed effects analysis carried out using the software NONMEM. A basic 
two compartment structure was used with constants and covariates from 
a model described by Henningsson et al(1). The covariates include age, 
performance status (PS) and body surface area (BSA).
Genotyping was carried out using Pyrosequencing on DNA extracted 
from whole blood.
Statistical considerations
Log transformed clearance of unbound paclitaxel seemed to be normal 
distributed (visually assesed). Hypothesis testing was thus carried out 
using multiple regression (test for trend) with control for age, BSA and PS. 
Analyses were carried out using STATA10.
In order to address the issue of multiple testing CYP2C8*3 and the three 
ABCB1 SNPs were selected before the statistical analysis was carried 
out. CYP2C8*4 and a host of other candidate genes were selected for 
explorative analysis, for which the P-values should be interpreted with caution. 
Conclusion
The genetic variant CYP2C8*3 is associated with approximately 11 % lower 
clearance of unbound paclitaxel than wild-type patients.
Clearance as function of CYP2C8*3 genotype; N=93
P−value 0.03
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Black diamonds mark clearance of patients using a CYP3A4 inhibitor.
In 93 patients: the 19 patients carrying the CYP2C8*3 genotype had 11 % 
lower clearance of unbound paclitaxel than patients without this genetic 
variant, P-value 0.03. The three ABCB1 SNPs were not signifi cantly 
associated to the clearance.
Explorative analysis: The 7 patients carrying the CYP2C8*4 genotype had 
18 % lower clearance, P-value 0.04.
Results
Hypothesis and Aim
The inter-individual variability in the clearance of paclitaxel is caused by 
CYP2C8*3 or ABCB1 SNPs: C1236T, G2677T/A or C3435T.
The aim of this study was to test the hypothesis in prospectively recruited 
patients with ovarian cancer treated with paclitaxel+carboplatin.
Introduction
Toxicity and therapeutic effects of paclitaxel vary greatly between patients 
and remain clinically relevant problems with implications on survival and 
quality of life. Paclitaxel is metabolized to inactive compounds mainly by 
CYP2C8 in the liver and is a substrate for P-glycoprotein encoded by the 
ABCB1 gene (MDR-1). We investigated the notion that single nucleotide 
polymorphisms (SNPs) in CYP2C8 and ABCB1 could be partly responsible 
for this variation through impact on the elimination.
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